NGAL: A potential biomarker to detect and follow persistent acute kidney injury (AKI)3

Introducing NGAL as a biomarker in addition to sCr will greatly improve diagnostic accuracy and reduce overall patient costs2,3,4.

Recent studies published demonstrates the clinical value of NGAL as a biomarker in addition to current AKI guidelines (KDIGO, AKIN, RIFLE), as the addition of NGAL is an advancement in the detection and prevention of AKI in critically ill patients. NGAL will at the same time introduce clinicians to overall costs savings2,3,4.

To learn more please click on the links below.

Strong data from previous NGAL study provides the basis for new protocol and FDA registration application

NGAL demonstrates positive economic outcome: Greatly reduces costs associated with diagnosis and treatment of acute kidney injury

Introduction to CSA-NGAL score - authored by an expert group chaired by Dr. Jean-Louis Vincent.

Please contact BioPorto Diagnostics for further informations or if you have any questions about The NGAL Test - CLICK HERE.


1. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a 269 multinational, multicenter study. JAMA. 2005;294:813-818.  Link.

2. de Geus HR, Ronco C, Haase M, Jacob L, Lewington A, Vincent J-L, The cardiac surgery-associated NGAL score: a potential tool to monitor acute tubular damage, The Journal of Thoracic and Cardiovascular Surgery (2016), doi: 10.1016/j.jtcvs.2016.01.037.  Link.

3. Tecson, KM. et. al Optimal cut points of plasma and urine neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury among critically ill adults: retrospective determination and clinical validation of a prospective multicentre study, BMJ Open; 2017; Jul10;7(7)e:016028. Link.

4. Parikh, A. et. al. Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine for acute kidney injury (AKI) diagnosis, PLoS One; 2017; May19; 12(5)e:178091. Link.